TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Physical Exercise for Augmenting Cognitive Health (PEACH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. adults aged 30-55 years~2. exposure to at least one form of threat-related adversity (e.g., exposure to violence; physical abuse) occurring prior to age 10 as documented by retrospective self-report~3. Self-identified Black or African American Race~4. access to high-speed internet~5. sedentary lifestyle (\<60 minutes of PA/week).~6. no difficulties with mobility~7. Does not currently require the use of an assisted walking device~8. Does not have a history of balance difficulties~9. Not currently pregnant or planning to become pregnant in the next 12 months~Exclusion Criteria:~1. Psychosis~2. Significant suicide risk (i.e., current, active suicidal ideation with a plan)~3. Engaging in moderate-intensity exercise \>=20 min per day, \>=3 times per week~4. Current treatment for cancer~5. Neurological condition (MS, Parkinson's, Dementia, MCI) or brain injury (Stroke)~6. Substance use disorder in the past 3-months~7. Current treatment for congestive heart failure, angina, uncontrolled arrhythmia, deep vein thrombosis (DVT) or other cardiovascular event~8. Myocardial infarction, coronary artery bypass grafting, angioplasty or other cardiac condition in the past year~9. Sensory Impairment that would preclude neuropsychological testing~10. Not fluent in English~11. Travelling consecutively for 2+ weeks during the study~12. uncontrolled hypertension~13. Insulin-Dependent Diabetes Mellitus~14. Self-identified race anything other than Black or African American~15. Currently pregnant or planning to become pregnant in the next 12 months

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Home-based aerobic exercise (Type: EXPERIMENTAL): Un-supervised exercise will be held 3 times a week for 60 minutes in the participant's home. Those who are unable to do a 60-minute session would instead complete it in two 30-minute sessions to reach the goal of exercising 150 minutes per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for primary unilateral knee arthroplasty with an expected discharge into an inpatient rehabilitation facility~* Hemoglobin \>11 to \<13 g/dL at screening and preoperative day -21~* Age 18 years or older~* Female subjects must be post-menopausal for at least one year or surgically sterile (hysterectomy or tubal ligation). Women of childbearing age must have negative pregnancy test(s) (serum HCG RIA at screening and urine at preoperative day -21, if applicable~* Preoperative lead time of at least 21 days~Exclusion Criteria:~* Medical conditions including: Known iron deficiency (defined as serum ferritin \<50 mg/l)~* chronic renal failure, significant hematological disease, uncontrolled hypertension, new onset seizures/uncontrolled seizures~* Expected to need another lower extremity major joint replacement within six months~* Undergoing cancer chemotherapy~* History of thrombotic vascular events including but not limited to stroke, transient ischemic attack, myocardial infarction and deep venous thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of NAC in Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 21 years~* able and agrees to drink alcohol~Exclusion Criteria:~* alcoholism (self-reported)~* pregnancy~* reactive airway disease~* diabetes~* kidney/bladder stones~* kidney disease~* liver disease~* stomach ulcer~* organ transplant patients~* dialysis patients~* allergies to alcohol, eggs, milk, or wheat~* volunteers taking the following medications: opiate pain medication, activated charcoal, ampicillin,carbamazepine, cephalosporidine, methicillin, nitroglycerine, oxacillin, penicillin G, quinicillin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
- N-acetyl cysteine (Type: EXPERIMENTAL): Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic phase Ph\^+ chronic myeloid leukemia (CML) demonstrating only a suboptimal response, defined as a hematologic response that is less than a complete hematologic response after at least 3 months of monotherapy with imatinib, 400 mg; a cytogenic response (CgR) that is less than a partial CgR (PCgR) after at least 6 months of monotherapy with imatinib, 400 mg; a PCgR after at least 12 months of monotherapy with imatinib, 400 mg; or less than a major molecular response with a complete CgR after at least 18 months of monotherapy with imatinib, 400 mg.~* Either gender~* Age of 18 years or older~Exclusion Criteria:~* Previous diagnosis of accelerated phase or blast crisis CML~* Uncontrolled or significant cardiovascular disease~* History of significant bleeding disorder unrelated to CML~* Concurrent malignancies~* Intolerance of imatinib, 400 mg~* Prior treatment with imatinib at a dose higher than 400 mg~* Prior stem cell transplantation and/or high-dose chemotherapy for CML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib (Type: ACTIVE_COMPARATOR): Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
- Imatinib (Type: ACTIVE_COMPARATOR): Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female~2. Postmenopausal women (defined as last menstrual period \> 1 year ago or 6 months ago with FSH \>40) who have been diagnosed with breast cancer including in situ carcinoma (DCIS, LCIS)~3. Have self-identified GSM signs and objective symptoms on baseline screening~4. Patients already using Replens™ or coconut oil will have a two week washout period prior to starting study treatment.~5. Medical History review and Pelvic Exam by a board certified gynecologist for baseline assessment OR medical records review by a board certified gynecologist or delegated study staff to confirm diagnosis of GSM. If GSM is to be verified by medical record review, the sub-investigator will make the final determination of eligibility.~Exclusion Criteria:~1. Use of any estrogen containing product within 4 weeks prior to screening~2. Endometrial hyperplasia, endometrial cancer, or other gynecologic malignancy~3. Patients with non GSM related signs and symptoms as verified by a board certified gynecologist will be excluded.~4. Any concurrent illness or disorder that, per the opinion of the investigator, would preclude the patient from meeting the study requirements.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Replens and coconut oil (Type: OTHER): Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing SVG PCI with a target vessel reference diameter ≤ 5.5 mm (visual estimate)~* Documented silent ischemia, stable angina pectoris Canadian Cardiovascular Society (CCS) class I to IV, or acute coronary syndrome~Exclusion Criteria:~* Previous stent implantation anywhere in the target SVG~* Concomitant native vessel PCI~* SVG age \<6 months~* Arterial grafts~* Oral anticoagulation~* Platelet count \<100x109/L or \>700x109/L, white blood cell count \<3000 cells/mm3~* Any major non-cardiac condition with a life expectancy \<12 months~* Planned elective surgery in the next 12 months~* Known allergies against the components tested~* Enrolled in other study~* No consent~* Patients unlikely to comply to the study treatment and the follow-up visits~* Age \<18 years~* Known pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Percutaneous coronary intervention
- 2 (Type: PLACEBO_COMPARATOR): Percutaneous coronary intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year for at least 30 days after the last fluorescein dye administration~* The study is being conducted in participants with GA in both Study Eye and Non-Study Eye (bilateral GA) with no evidence of prior or active choroidal neovascularization (CNV)~Exclusion Criteria:~* Previous participation in any studies of investigational drugs for GA or dry AMD (except for studies of vitamins and minerals)~* GA in either eye due to causes other than AMD~* History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD~* Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy~* Any ocular or systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments~* Requirement for continuous use of therapy indicated in Prohibited Therapy in the study Protocol

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort Geographic Atrophy (Type: None): Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a history of systemic diabetes (type I or II)~* Subject with a documented history of Non Proliferative Diabetic Retinopathy (NPDR)~* Subjects with no PVD at baseline exam in the study eye.~Exclusion Criteria:~* Subjects with Retinal pathology in the study eye other than (NPDR)~* Subjects with high myopia in the study eye~* Subjects who have monocular vision or contra lateral vision of 20/200 or worse BCVA in the non-study eye.~* Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less than 6 months prior to study enrollment~* Subjects that have had either vitrectomy surgery, intravitreal injections, or laser treatments in the study eye.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Females who are postmenopausal or who no longer wish to bear children~* Females \>25 years old and \<65 years old~* Diagnosis of biliary disease requiring cholecystectomy~* American Society of Anesthesiology (ASA) Class I or II~* Females who are able to understand and willing to sign an informed consent document~Exclusion Criteria:~* Pregnancy~* BMI \>= 30~* Patients who are still interested in childbearing~* Patients taking immunosuppressive medications or who are immunocompromised~* Patients with acute cholecystitis or history of acute cholecystitis ( as defined by right upper quadrant pain with history of fevers and/or elevated white blood cell count and/or positive ultrasound findings, ie, gallbladder wall thickening or pericholecystic fluid)~* Patients with suspicion of gallbladder cancer~* Patients with history of previous open abdominal surgery~* Patients with untreated common bile duct stones

- Gender: FEMALE
- Minimum Age: 26 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Decellularised Dermis Allograft for the Treatment of Chronic Venous Leg Ulceration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years or older (no upper age limit)~* The ability to consent to participation~* A diagnosis of venous leg ulceration\* (defined as 'colour duplex confirmation of superficial and or deep venous reflux with any break in the skin that has either: a) been present for more than 2 weeks, or b) occurred in a person with a history of venous leg ulceration)~* Documented venous incompetence on duplex ultrasound~* Index ulcer wound duration of greater than 3 months~* Index ulcer wound size ≥ 2 cm2.~* ABPI ≥ 0.8~  * in light of the Covd-19 pandemic, the use of handheld continuous wave Dopplers will be allowed to diagnose venous disease to allow participants to be recruited from clinic without the need for an imaging appointment~Exclusion Criteria:~* A diagnosis of sickle cell~* Unable to receive one or more of the randomised treatment strategies for any reason at the discretion of the attending clinical team (e.g. known allergies to dCELL dermis preparation components)~* A clinically infected ulcer defined as evidence of erythema, cellulitis or systemically unwell~* Treatment with biomedical/topical growth factors within previous 30 days~* Previous history of an inability to tolerate compression therapy~* Foot ulcer (i.e. below the ankle)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care arm (Type: ACTIVE_COMPARATOR): Compression bandaging therapy as per standard care
- DCD Arm (Type: EXPERIMENTAL): DCD graft plus compression bandaging therapy as per standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Automated Postoperative Sedation After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiac surgical procedure requiring postoperative sedation~* Low operative risk : EuroSCORE 2 ≤ 5%~* Consent for participation~* Affiliation to the social security system~Exclusion Criteria:~* Pregnant or breastfeeding women~* Neurological or muscular disorder~* Pacemaker~* Hypersensitivity to propofol or remifentanil~* Communication difficulties or neuropsychiatric disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Automated postoperative sedation (Type: EXPERIMENTAL): Automated administration of Propofol and Remifentanil.
- Manual postoperative sedation (Type: ACTIVE_COMPARATOR): Manual administration of Propofol and Remifentanil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma (AC) or squamous cell carcinoma of the esophagus~  * AC of the gastroesophageal junction allowed~* Tumor must be considered surgically resectable (T1-3, NX)~  * No early-stage cancer (T1, N0)~* The following lymph node (LN) criteria are considered acceptable:~  * Regional thoracic LN metastases (N1)~ * LN metastases levels 15 to 20 measured as ≤ 1.5 cm by CT scan~ * Supraclavicular LN not palpable on clinical examination measured as ≤ 1.5 cm by CT scan~* No distant metastases (M0)~PATIENT CHARACTERISTICS:~* Platelet count ≥ 100,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Hemoglobin ≥ 9.0 g/dL~* Creatinine clearance ≥ 50 mL/min~* Creatinine serum level ≤ CTC grade 2~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* AST \< 3 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No known severe hypersensitivity to gefitinib or any of its excipients~* No evidence (except asymptomatic chronic stable radiographic changes) of clinically active interstitial lung disease~* No pulmonary fibrosis, Gilbert's disease, uncontrolled diabetes mellitus, or unstable angina~* No New York Heart Association class III or IV heart disease~* No other concurrent malignancies or malignancies diagnosed within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix~* No serious active or uncontrolled infection, systemic disease, psychiatric illness, or other medical condition that would preclude study participation~* No evidence of any significant clinical disorder or laboratory finding that would preclude study participation~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for esophageal cancer~* No prior radiotherapy that would overlap the study treatment fields~* Recovered from prior major surgery~* No nonapproved or investigational drugs within the past 30 days~* No concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or Hypericum perforatum (St. John's wort)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues